Summary: Zevra Therapeutics announced that Rene Braeckman, PhD, the company’s senior vice president of clinical development, will present top-line data from the phase 2 clinical trial of KP1077 (serdexmethylphenidate) in patients with idiopathic hypersomnia (IH) at Sleep Europe … [Read more...]
Alkermes to Present Data on ALKS 2680 for Narcolepsy Type 2 and Idiopathic Hypersomnia
Summary: Alkermes plc is set to present data from its phase 1b study of ALKS 2680, a novel oral orexin 2 receptor agonist, at Sleep Europe 2024. The study evaluated ALKS 2680 in patients with narcolepsy type 2 and idiopathic hypersomnia, showing improved wakefulness compared to … [Read more...]
Narcolepsy, Idiopathic Hypersomnia Study Reinforces Importance of Individualized Oxybates Dosing
By Sree Roy When starting people with narcolepsy and idiopathic hypersomnia on oxybates, sleep physicians know to individualize the treatment dosing based on each patient’s response as well as personal preference. A new study presented at SLEEP 2024 reinforces the importance of … [Read more...]